AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19948872
Drug: GFR <60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GFR <60 ml/min/1.73 m(2)
Trial: 19948872
Drug: GFR <60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GFR <60 ml/min/1.73 m(2) in women without pre-existing CVD
Trial: 17627004
Drug: Combination low-fat/high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination low-fat/high fruit-vegetable diet
Trial: 8645892
Drug: Moderate hydration
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate hydration plus ANP infusion (ANP group)
Trial: 10411764
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam premedication
Trial: 7871107
Drug: Established biological
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Established biological risk factors (serum low-density lipoprotein cholesterol concentration, smoking, old age)
Trial: 3175455
Drug: Decreased spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decreased spray cone angle from 60 degrees to 35 degrees
Trial: 30094707
Drug: Adjuvant radiochemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant radiochemotherapy and chemotherapy
Trial: 27038440
Drug: betamethasone valerate
RxNorm normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: betamethasone valerate cream
Trial: 27038440
Drug: roflumilast 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roflumilast 0.5% cream
Trial: 27038440
Drug: TAK‐084 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK‐084 0.5% cream
Trial: 27038440
Drug: TAK‐084 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK‐084 5% cream
Trial: 27038440
Drug: calcipotriol 0.005%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: calcipotriol 0.005% cream
Trial: 23601333
Drug: Antibiotics (norfloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (norfloxacin 400 mg BD)
Trial: 23601333
Drug: Antibiotics (norfloxacin)
RxNorm normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotics (norfloxacin)
Trial: 20152700
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dyssynchrony with epsilon-pl < -7.8%
Trial: 2019161
Drug: Metaproterenol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metaproterenol (5 percent solution, 0.3 ml) plus atropine sulfate (2.5 mg)
Trial: 2019161
Drug: Metaproterenol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metaproterenol (5 percent solution, 0.3 ml) alone
Trial: 28758951
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (Fe condition) - 12 mg of iron twice daily (24 mg/day)
Trial: 18007083
Drug: Low tidal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low tidal volume ventilation (6 mL/kg)
Trial: 23880084
Drug: High tidal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High tidal volume ventilation (12 mL/kg)
Trial: 26725184
Drug: Erlotinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (150 mg orally daily)
Trial: 11468032
Drug: Etifoxine 50
RxNorm normalized name: etifoxine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etifoxine 50 mg
Trial: 11468032
Drug: Etifoxine 100
RxNorm normalized name: etifoxine
DrugBank: Etifoxine (DB08986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etifoxine 100 mg
Trial: 9763356
Drug: Vitamins (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamins (specific type and dosage not mentioned)
Trial: 28376756
Drug: Ultrasound guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound guided needling and lavage (barbotage) with subacromial steroid injection
Trial: 28376756
Drug: Sham barbotage
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham barbotage with subacromial steroid injection
Trial: 28376756
Drug: Sham barbotage
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham barbotage without subacromial steroid injection (placebo group)
Trial: 21450115
Drug: dairy-Se (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dairy-Se (150 μg/d)
Trial: 21450115
Drug: yeast-Se (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: yeast-Se (150 μg/d)
Trial: 15483410
Drug: Aselizumab 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aselizumab 0.5 mg/kg
Trial: 15483410
Drug: Aselizumab 1
RxNorm normalized name: atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Aselizumab 1 mg/kg
Trial: 15483410
Drug: Aselizumab 2
RxNorm normalized name: atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Aselizumab 2 mg/kg
Trial: 7835118
Drug: Low dosage
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dosage growth hormone (GH) co-administered with gonadotropin (Gn)
Trial: 3293642
Drug: Adrenaline 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline 0.2 ml (0.2 mg) with 5% lignocaine 2 ml in 7.5% dextrose
Trial: 3293642
Drug: Adrenaline 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline 0.4 ml with 5% lignocaine 2 ml in 7.5% dextrose
Trial: 3293642
Drug: 5% lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% lignocaine 2 ml in 7.5% dextrose with physiological saline 1 ml
Trial: 31838113
Drug: Oxygen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen therapy at 6 l/min for 6 to 12 hours
Trial: 19950305
Drug: Multidisciplinary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary treatment for fibromyalgia
Trial: 17242147
Drug: Apricitabine at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apricitabine at 600 mg twice daily
Trial: 17242147
Drug: Apricitabine at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apricitabine at 600 mg twice daily with lamivudine at 300 mg once daily
Trial: 17242147
Drug: Lamivudine at
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine at 300 mg once daily
Trial: 8009342
Drug: Oxytocin antagonist
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin antagonist [d(CH2)5, Tyr(Me)2, Orn8]-vasotocin
Trial: 8009342
Drug: Opiate receptor-blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opiate receptor-blocker naloxone
Trial: 8009342
Drug: Oxytocin antagonist
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin antagonist
Trial: 28059417
Drug: 22 g
RxNorm normalized name: Empty Carpuject 2 mL 22 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22 g freeze‐dried highbush blueberry powder per day
Trial: 28059417
Drug: 22 g
RxNorm normalized name: Empty Carpuject 2 mL 22 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22 g placebo powder per day
Trial: 19039454
Drug: Topical latanoprost
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Topical latanoprost (n=10)
Trial: 14600698
Drug: Quantec‐E irrigation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quantec‐E irrigation pump with 12 mL of 5.25% NaOCl, followed by 6 mL EDTA 17%, and a final flush with 4 mL 5.25% NaOCl
Trial: 8729158
Drug: Dermagraft (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dermagraft (one piece applied weekly for 8 weeks)
Trial: 30149850
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave therapy
Trial: 20237063
Drug: Zinc treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc treatment (20 mg/d for 10 days)
Trial: 20237063
Drug: Zinc treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc treatment plus supplementation (10 mg/d for 3 months after initial treatment)
Trial: 20237063
Drug: Zinc treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc treatment (ZT)
Trial: 20237063
Drug: Zinc treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc treatment plus supplementation (ZT+S)
Trial: 18537187
Drug: G-CSF (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (10 microg/kg/day for 5 days)
Trial: 1451291
Drug: Topical isotretinoin
RxNorm normalized name: isotretinoin Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical isotretinoin 0.05%
Trial: 6548348
Drug: Other anti-emetic
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other anti-emetic drugs
Trial: 29843553
Drug: Ferrous bis-glycinate
RxNorm normalized name: ferrous bis-glycinate HCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferrous bis-glycinate tablets once daily for eight consecutive weeks
Trial: 29843553
Drug: Ferrous glycine
RxNorm normalized name: Ferrous glycine sulfate
DrugBank: Ferrous glycine sulfate (DB14501)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferrous glycine sulfate capsules once daily for eight consecutive weeks
Trial: 29436624
Drug: Lou type
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lou type equation for warfarin dosing
Trial: 20179126
Drug: Multi-component physical
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-component physical activity programme (n=297) including structured physical education lessons, additional lessons, daily activity breaks, and homework.
Trial: 16351361
Drug: Response compatibility
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Response compatibility processes (e.g., Implicit Association Test, affective priming with an evaluative decision task)
Trial: 16351361
Drug: Stimulus compatibility
RxNorm normalized name: Limulus polyphemus extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulus compatibility processes (e.g., semantic priming with a lexical-decision task)
Trial: 31366053
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g baru almonds (BARU)
Trial: 26503312
Drug: N-acetylcysteine (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (240 mg/kg over 12 h)
Trial: 24657122
Drug: MenACWY‐CRM booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY‐CRM booster dose
Trial: 10072015
Drug: Adenosine (ADO)
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine (ADO) infusion (60 microg x kg(‐1) x min(‐1))
Trial: 21775560
Drug: Antioxidant supplementation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplementation (daily vitamin C 120 mg, β-carotene 6 mg, vitamin E 30 mg, selenium 100 μg, zinc 20 mg)
Trial: 20023348
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (electrotherapy and lumbar strengthening exercises)
Trial: 11686810
Drug: Ready-to-use Emdogain-gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ready-to-use Emdogain-gel
Trial: 9542288
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of plethysmography, vibrometry, two point discrimination, and monofilament testing
Trial: 3166942
Drug: Grenz rays
RxNorm normalized name: Ray Dol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grenz rays alone (4 Gy administered on six occasions at intervals of 1 week)
Trial: 3166942
Drug: Grenz rays
RxNorm normalized name: Ray Dol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grenz rays combined with topical corticosteroid (betamethasone dipropionate)
Trial: 25466700
Drug: Oral sildenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sildenafil 20 or 40 mg p.o. t.i.d. for 6 weeks
Trial: 20886505
Drug: Single Pulse
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Pulse treatment
Trial: 20886505
Drug: Double Pulse
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double Pulse treatment
Trial: 8840852
Drug: Ibutilide (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibutilide (1.0 and 0.5 mg or 1.0 and 1.0 mg)
Trial: 1531484
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg in fasting state
Trial: 1531484
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg in nonfasting state
Trial: 27341450
Drug: Dexmedetomidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1 μg/kg) combined with lidocaine
Trial: 18729147
Drug: Internet delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet delivered cognitive behavior therapy combined with five group exposure sessions (ICBT+ exp)
Trial: 12634652
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment (oral regimens with treatment durations of > or =7 days)
Trial: 3935853
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment (general)
Trial: 12634652
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment (low-risk patients)
Trial: 12634652
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment (vaginal regimens)
Trial: 12634652
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment in patients with preterm labor
Trial: 8768849
Drug: Pyridostigmine (PD;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine (PD; 120 mg, orally)
Trial: 8768849
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PD and Pirenzepine (PZP; 100 mg, orally)
Trial: 6637785
Drug: Alpha-adrenergic blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-adrenergic blocker prazosin
Trial: 30919809
Drug: 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg intravenous tranexamic acid dissolved in 100 mL of saline (TXA group)
Trial: 30919809
Drug: 100 mL
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL of saline solution (placebo group)
Trial: 17538537
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil containing parenteral nutrition (FO: Lipoplus: LCT40%-MCT50%-FO10%)
Trial: 17538537
Drug: Standard parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard parenteral nutrition (STD: Lipofundin medium‐chain triglyceride (MCT): long‐chain triglyceride (LCT)50%-MCT50%)
Trial: 17538537
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil containing parenteral nutrition (FO)
Trial: 16842478
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro mixture 25/75 (Mix 25/75)
Trial: 12850677
Drug: Initial conservative
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial conservative treatment followed by delayed laparoscopic cholecystectomy (6 to 8 weeks later)
Trial: 11350436
Drug: Oral lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lithium gamolenate (700 mg daily for 15 days)
Trial: 11350436
Drug: Low-dose intravenous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intravenous lithium gamolenate (0.28 g/kg)
Trial: 11350436
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous lithium gamolenate (0.84 g/kg)
Trial: 11350436
Drug: Low-dose intravenous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intravenous lithium gamolenate with haemolysis
Trial: 9303285
Drug: Rocuronium infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium infusion during propofol-nitrous oxide anaesthesia
Trial: 9303285
Drug: Rocuronium infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium infusion during isoflurane-nitrous oxide anaesthesia
Trial: 8134777
Drug: Ivermectin 100
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin 100 micrograms/kg single dose
Trial: 29858911
Drug: Placebo (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (40 mg)
Trial: 21056658
Drug: Sugar esters
RxNorm normalized name: lutein esters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar esters proniosomes (SEs) for transdermal delivery of vinpocetine
Trial: 21056658
Drug: Oral tablet
RxNorm normalized name: Oral Tablet
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablet of vinpocetine
Trial: 14556923
Drug: Letrozole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (2.5 mg per day)
Trial: 14556923
Drug: Anastrozole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole (1 mg per day)
Trial: 1580636
Drug: Methionine-deprived amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionine-deprived amino acid solution (AO-90)
Trial: 1580636
Drug: Conventional amino
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional amino acid solution (control group)
Trial: 3022852
Drug: C.O.P.A.C. combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C.O.P.A.C. combination (Cyclophosphamide, Vincristine, Cis‐Platinum, Adriamycin and CCNU)
Trial: 22146780
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment for 10 weeks in addition to best medical care
Trial: 18328872
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment for PTSD
Trial: 19005898
Drug: Torasemide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torasemide (5 mg/day) at bedtime
Trial: 19005898
Drug: Torasemide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torasemide (5 mg/day) upon awakening
Trial: 14571073
Drug: Medium-dose UVA1
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose UVA1 phototherapy (48 J/cm2), treated 4 times a week for 5 weeks.
Trial: 8923573
Drug: Dihydroergocristine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroergocristine (2 x 3 mg/day)
Trial: 31433997
Drug: Tobramycin inhalation
RxNorm normalized name: Tobramycin Inhalation Powder
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin inhalation powder (TIP) administered in three different daily doses as continuous or cyclical regimens for 112 days of double-blind treatment.
Trial: 31433997
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered in a double-blind manner for 112 days of treatment.
Trial: 22228885
Drug: L-ornithine L-aspartate
RxNorm normalized name: L-ornithine L-aspartate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-ornithine L-aspartate (LOLA) infusion
Trial: 19370275
Drug: Fentanyl 1.5
RxNorm normalized name: fentanyl 1.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 1.5 mcg.kg‐1 during induction
Trial: 19370275
Drug: Fentanyl 1.5
RxNorm normalized name: fentanyl 1.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 1.5 mcg.kg‐1 during induction and Propofol 1 mg.kg‐1 at the end of surgery
Trial: 16820557
Drug: BMC group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMC group (CABG and injection of 60.10(6)+/‐31.10(6) BMC)
Trial: 8147961
Drug: Zinc (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc (25 mg/d)
Trial: 3752487
Drug: Methohexitone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methohexitone (2 mg/kg)
Trial: 31481323
Drug: Surgery for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery for closed ankle fractures with antibiotic prophylaxis
Trial: 21051425
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL PRP (10 times higher platelet concentration than peripheral blood)
Trial: 21051425
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL PRP